COMMUNIQUÉS West-GlobeNewswire

Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed [...]
Immunocore reports first quarter financial results and provides a business update
06/05/2026
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles [...]
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
06/05/2026
Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 – Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients enrolled; [...]
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront [...]
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
06/05/2026
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
06/05/2026
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to [...]
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
06/05/2026
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.) TONMYA (cyclobenzaprine HCl sublingual [...]
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
06/05/2026
First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued [...]
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
06/05/2026
100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1) Favorable safety [...]
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
06/05/2026
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s [...]
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
06/05/2026
EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue [...]
Hyperion DeFi Announces Pricing of Public Offering of Common Stock
06/05/2026
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced the pricing of a [...]
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
06/05/2026
First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and [...]
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
06/05/2026
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
06/05/2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
06/05/2026
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United [...]
Recursion Reports First Quarter Financial Results and Provides Business Update
06/05/2026
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose- [...]
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
06/05/2026
Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company [...]
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
06/05/2026
Lyon (France), May 6 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The [...]

Pages